Seeing Is Believing
SGMT is currently covered by 8 analysts with an average price target of $27.36. This is a potential upside of $19.34 (241.15%) from yesterday's end of day stock price of $8.02.
Sagimet Biosciences Series A Common Stock's activity chart (see below) currently has 24 price targets and 48 ratings on display. The stock rating distribution of SGMT is 85.71% BUY, 9.52% HOLD and 4.76% SELL.
Analysts average stock forecasts to be materialized ratio is 6.86% with an average time for these price targets to be met of 19.06 days.
Highest price target for SGMT is $56, Lowest price target is $7, average price target is $27.36.
Most recent stock forecast was given by BRANDON FOLKES from HC WAINWRIGHT on 05-Oct-2026. First documented stock forecast 08-Aug-2023.
Currently out of the existing stock ratings of SGMT, 18 are a BUY (85.71%), 2 are a HOLD (9.52%), 1 are a SELL (4.76%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 07-Aug-2025
$29
$20.98 (261.60%)
$29
12 days ago
(05-Oct-2026)
0/4 (0%)
$19.97 (221.15%)
Buy Since 02-Feb-2026
$26
$17.98 (224.19%)
$25
15 days ago
(02-Oct-2026)
0/3 (0%)
$16.86 (184.46%)
Buy Since 08-Aug-2023
$27
$18.98 (236.66%)
$29
16 days ago
(01-Oct-2026)
0/6 (0%)
$17.63 (188.15%)
Buy Since 04-Dec-2024
$38
$29.98 (373.82%)
$33
16 days ago
(01-Oct-2026)
0/6 (0%)
$28.63 (305.55%)
Sell Since 24-Sep-2026
$7
$-1.02 (-12.72%)
23 days ago
(24-Sep-2026)
1/6 (16.67%)
$-2.11 (-23.16%)
128
What is SGMT (Sagimet Biosciences Series A Common Stock) average time for price targets to be met?
Which analyst most recently updated their price target on SGMT (Sagimet Biosciences Series A Common Stock)?
Which analyst has the most public recommendations on SGMT (Sagimet Biosciences Series A Common Stock)?
Which analyst is the currently most bullish on SGMT (Sagimet Biosciences Series A Common Stock)?
Which analyst is the currently most reserved on SGMT (Sagimet Biosciences Series A Common Stock)?